Six‐Month Real‐World Effectiveness, Persistence and Safety of Low‐to‐Moderate Dose Tirzepatide in Adults With Obesity: A Multicentre Observational Study
Diabetes, Obesity and Metabolism · 2026-07 · 28 (7) · 6113-6120
DOI: 10.1111/dom.70810 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Diabetes, Obesity and Metabolism, online erschienen am 27.04.2026. Verfasst von Nikolaos Angelopoulos und 14 weiteren Autor:innen. Beteiligte Einrichtung: Hellenic Endocrine Network, Athens, Greece. Hauptthemen laut MEDLINE: Anti-Obesity Agents, Obesity, Tirzepatide. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 23 Literaturangaben.
Abstract (Originalsprache)
Aims
To evaluate 6‐month weight‐loss outcomes, treatment persistence, and safety of low‐ to moderate‐dose tirzepatide in a real‐world clinical setting.
Methods
This multicentre retrospective observational study evaluated adults with obesity who initiated tirzepatide in routine clinical practice across 15 endocrinology clinics in Greece between December 2024 and May 2025. Patients with available baseline and 6‐month follow‐up (±2 weeks) data were included. Changes in body weight and body mass index (BMI) were assessed, while treatment persistence, reasons for discontinuation, and adverse events were recorded. Continuous variables were analysed using paired parametric or non‐parametric tests as appropriate.
Results
A total of 260 patients initiated tirzepatide, of whom 208 (80%) completed 6 months of therapy. Median percentage weight loss was substantial, with 94.2% achieving ≥ 5% weight loss, 77.9% ≥ 10%, 47.1% ≥ 15% and approximately 20% ≥ 20%. Body weight and BMI decreased significantly from baseline ( p < 0.001), with a large effect size. Weight‐loss magnitude was independent of baseline BMI and obesity class, while women achieved a greater percentage weight loss than men ( p = 0.042). Treatment discontinuation occurred in 20% of patients, most commonly during the titration phase, primarily due to goal achievement, cost, non‐response or adverse events. Gastrointestinal adverse events were the most frequently reported but rarely led to treatment discontinuation.
Conclusions
In routine clinical practice, low‐to‐moderate dose tirzepatide was associated with clinically meaningful weight loss at 6 months, high treatment persistence, and acceptable tolerability. These findings provide real‐world evidence supporting the medium‐term effectiveness of tirzepatide across obesity severity in everyday endocrinology practice. Trial Registration ACTRN12625000071426
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Hellenic Endocrine Network, Athens, Greece.
- Mediterranean Diabetes and Obesity Clinics (MEDOC), Athens, Greece.
- Department of Endocrinology, Metropolitan General Hospital, Athens, Greece.
- First Medical Propedeutic Department of Internal Medicine, AHEPA University Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece.
- Division of Diabetes, Endocrinology and Gastroenterology, School of Medical Sciences, University of Manchester, Manchester, UK.
- Division of Medicine, Department of Metabolism & Experimental Therapeutics, University College London Medical School, London, UK.
ORCID-Profile: Nikolaos Angelopoulos
Zitieren
APA
Angelopoulos, N., Zianni, D., Livadas, S., Androulakis, I., Fousteris, E., Paparodis, R., Petkova, V., Florakis, D., Mouslech, Z., Rizoulis, A., Perogamvros, I., Tzoulis, P., Askitis, D., Argyrakopoulou, G., & Lambadiari, V. (2026). Six‐Month Real‐World Effectiveness, Persistence and Safety of Low‐to‐Moderate Dose Tirzepatide in Adults With Obesity: A Multicentre Observational Study. Diabetes, Obesity and Metabolism, 28(7), 6113-6120. https://doi.org/10.1111/dom.70810
Vancouver
Angelopoulos N, Zianni D, Livadas S, Androulakis I, Fousteris E, Paparodis R, et al. Six‐Month Real‐World Effectiveness, Persistence and Safety of Low‐to‐Moderate Dose Tirzepatide in Adults With Obesity: A Multicentre Observational Study. Diabetes, Obesity and Metabolism. 2026;28(7):6113-6120. doi:10.1111/dom.70810
BibTeX
@article{Angelopoulos2026,
author = {Angelopoulos, Nikolaos and Zianni, Dimitra and Livadas, Sarantis and Androulakis, Ioannis and Fousteris, Evangelos and Paparodis, Rodis and Petkova, Valentina and Florakis, Dimos and Mouslech, Zadalla and Rizoulis, Andreas and Perogamvros, Ilias and Tzoulis, Ploutarchos and Askitis, Dimitrios and Argyrakopoulou, Georgia and Lambadiari, Vaia},
title = {Six‐Month Real‐World Effectiveness, Persistence and Safety of Low‐to‐Moderate Dose Tirzepatide in Adults With Obesity: A Multicentre Observational Study},
journal = {Diabetes, Obesity and Metabolism},
year = {2026},
volume = {28},
number = {7},
pages = {6113--6120},
doi = {10.1111/dom.70810}
}
EUVIMED